Rhythm Pharmaceuticals upgraded by BofA Securities with a new price target
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care
BofA Securities upgraded Rhythm Pharmaceuticals from Neutral to Buy and set a new price target of $63.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/14/2025 | $130.00 | Mkt Perform → Mkt Outperform | Citizens JMP |
| 7/10/2025 | $97.00 | Buy | Goldman |
| 7/7/2025 | $88.00 | Outperform | Leerink Partners |
| 4/7/2025 | $63.00 | Neutral → Buy | BofA Securities |
| 3/5/2025 | $78.00 | Buy | Stifel |
| 1/2/2025 | $80.00 | Buy | Jefferies |
| 12/20/2024 | $76.00 | Outperform | Oppenheimer |
| 10/21/2024 | $70.00 | Buy | Guggenheim |
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with prior use or concomitant use of GLP-1s - BOSTON, July 12, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced data from three new presentations on the Company's clinical programs for acquired hypothalamic obesity at the Endocrine Society's Annual Meeting (ENDO 2025) taking place July 12-15 in Sa
BOSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) ("Rhythm"), a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases, today announced the pricing of its upsized public offering of 2,058,824 shares of its common stock at a public offering price of $85.00 per share. In addition, Rhythm also granted the underwriters a 30-day option to purchase up to an additional 308,823 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering are expected to be approximately $175 million, before deducting un
BOSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) ("Rhythm"), a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases, today announced a proposed public offering of $150 million of its common stock. All securities in the offering will be offered by Rhythm. In addition, Rhythm intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of common stock at the public offering price, less the underwriting discounts and commissions. Morgan Stanley, BofA Securities, Stifel and Wells Fargo Securities are acting as joint book-runnin
4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
Citizens JMP upgraded Rhythm Pharmaceuticals from Mkt Perform to Mkt Outperform and set a new price target of $130.00
Goldman initiated coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $97.00
Leerink Partners initiated coverage of Rhythm Pharmaceuticals with a rating of Outperform and set a new price target of $88.00
8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
424B5 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
424B5 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
-- Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks -- -- Post-hoc analysis showed BMI reductions in bivamelagon trial were consistent with BMI reductions achieved by setmelanotide in past trials in similar patient populations -- -- Patients in both 600mg and 400mg cohorts achieved mean reduction of -2.8 points in most hunger scores -- -- Limited instances of localized hyperpigmentation observed -- -- Rhythm to request End-of-Phase 2 meeting with U.S. FDA in order to pursue registrational path for bivamelagon in acquired hypothalamic obesity -- -- Company to host conference cal
BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the Company will hold a conference call and webcast on Wednesday, July 9, 2025 at 8:00 a.m. ET to disclose topline results from the randomized, placebo-controlled portion of the Phase 2 trial evaluating bivamelagon, an investigational oral melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity. Conference Call InformationRhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET on Wednesday,
-- First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity -- -- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 -- -- Topline data from Phase 2 trial of oral MC4R agonist bivamelagon on track to be announced in third quarter of 2025 -- -- Cash on-hand expected to support planned operations into 2027 -- -- Management to host conference call today at 8:00 a.m. ET -- B
SC 13G - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair "Al" Garfield, Ph.D. as Chief Scientific Officer, effective July 1. "We are excited to welcome Al back to Rhythm as we continue to leverage our understanding of the melanocortin-4 receptor (MC4R) pathway to bring potential therapies to patients and their families," said David Meeker, M.D., Rhythm Chairman, Chief Executive Officer and President. "Al's leadership and established scientific expertise and experience
BOSTON, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced the appointment of Dana Washburn, M.D., as Senior Vice President of Clinical Development and as a member of the Company's Executive Leadership Team, effective September 26, 2022. As SVP of Clinical Development, Dr. Washburn will lead the Company's robust clinical development program, clinical operations, and data management. "Dr. Washburn is a collaborative, resourceful leade
Wren Therapeutics, a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, today announced the appointment of Bart Henderson as Chief Executive Officer. Wren's unique drug discovery platform harnesses advances in the biophysics of protein assembly dynamics to target the toxic fleeting protein intermediates, the oligomers, in neurodegenerative disease pathways, and discover small molecules that can block their generation with precision. Bart brings broad leadership experience in the biotechnology industry as a founder and co-founder of several companies including Torque (now Repertoire Immune Medicines), Rhythm (NASDAQ:RYTM) and its subsidiary Motus (acquired